Research & Development

Mark Burkard on the Future of Precision Breast Cancer Care
Research & Development Mark Burkard on the Future of Precision Breast Cancer Care

The actionability gap in genomic testing remains a significant hurdle, as physicians frequently identify mutations for which no effective targeted therapies currently exist. This discrepancy underscores a profound shift in modern oncology where the bottleneck is no longer the ability to map the

How Do Gold Nanostructures Optimize Cancer Heat Therapy?
Research & Development How Do Gold Nanostructures Optimize Cancer Heat Therapy?

Gold nanoparticles demonstrate a unique capacity to absorb near-infrared light and convert it into precise thermal energy capable of destroying malignant cells without damaging all surrounding healthy tissue. This specific characteristic, known as the photothermal effect, has transformed

Human Amniotic Membrane Advances in Regenerative Medicine
Research & Development Human Amniotic Membrane Advances in Regenerative Medicine

Injectable amniotic membrane powder is being investigated for its disease-modifying potential in treating osteoarthritis, as it contains factors that suppress enzymes responsible for cartilage breakdown. This transition from a specialized tool in ophthalmology to a cornerstone of orthopedics and

Can 212Pb-ADVC001 Transform Advanced Prostate Cancer Care?
Research & Development Can 212Pb-ADVC001 Transform Advanced Prostate Cancer Care?

While 177Lu-PSMA-617 has improved survival, many patients eventually see their cancer progress as the disease develops resistance to beta-particle radiation. This clinical hurdle has forced researchers to look beyond standard therapies toward the high-energy potential of alpha-emitting isotopes.

Lilly’s Retatrutide Outperforms Ozempic in Weight Loss Study
Research & Development Lilly’s Retatrutide Outperforms Ozempic in Weight Loss Study

The 12 mg dose of retatrutide helped patients lose more than one-fifth of their body weight, setting a new benchmark for pharmacological obesity interventions. This milestone represents a paradigm shift in the treatment of chronic metabolic conditions, moving beyond simple blood sugar regulation

Cancer Trial Gains Bring New Questions for Everyday Care
Research & Development Cancer Trial Gains Bring New Questions for Everyday Care

Patients receiving Roche’s divarasib lived a median of roughly 18 months in a Phase 3 lung cancer trial, compared with about 12 months among those receiving Krazati or Lumakras. That finding, presented at the European Society for Medical Oncology meeting, sits alongside encouraging results for a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later